The Quantellect read.As of Nov 19, 2026, 10 active firms cover Avalo Therapeutics Inc: 8 rate it Buy or better, 2 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. The target range is very wide, $10.00 to $60.00 (about 6.0x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $39.10 sits 483% above the current $6.71. The rating mix has stayed broadly stable, with Buy-side ratings easing from 10 to 8 over recent months. On the fundamentals, the Street sees revenue growth near -100% this year and 0% next, consensus EPS building from about $-0.62 next quarter toward $-2.62 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS10 active firms
Buy
Strong Buy00%
Buy880%
Neutral220%
Sell00%
Strong Sell00%
Based on 10 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$39.10
+482.7% upside
Average target across 10 active firms as of Nov 19, 2026 vs $6.71 current
Highest Target$60.00
Average Target$39.10
Lowest Target$10.00
Detailed analyst forecasts for AVTX
Showing 1–11 of 11 named analysts shown · 10 active firms in the rating projection
As of Nov 19, 2026, 8 of 10 active firms rate AVTX a Buy (2 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
AVTX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.62
Range $-0.74 – $-0.54 · 4 analysts · -37% YoY
Next period, 4 analysts expect Avalo Therapeutics Inc to earn $-0.62 a share (range $-0.74 – $-0.54), versus $-0.98 a year earlier. Full-year consensus is $-2.35, growing to $-2.62 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 4 analysts · +0% YoY
Revenue is expected to reach $0 (range $0 – $0), +0.0% year-over-year. Full-year consensus is $0, rising to $0 next year.
Top analysts covering Avalo Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on AVTX.
#1
Jason Butler
JMP Securities · Rank #62
Buy
$55.00+719.7% to target
Overall win rate
49%
+ Follow
#2
Yatin Suneja
Guggenheim · Rank #84
Neutral
No targeton AVTX
Overall win rate
50%
+ Follow
#3
Julian Harrison
BTIG · Rank #183
Buy
$10.00+49.0% to target
Overall win rate
41%
+ Follow
#4
Mitchell Kapoor
HC Wainwright & Co. · Rank #305
Neutral
No targeton AVTX
Overall win rate
33%
+ Follow
#5
Yasmeen Rahimi
Piper Sandler · Rank #339
Buy
$60.00+794.2% to target
Overall win rate
30%
+ Follow
AVTX stock forecast FAQ
What is AVTX's average 12-month price target?+
The 10 active firms with a live target average $39.10 for Avalo Therapeutics Inc over the next 12 months, ranging from a $60.00 high to a $10.00 low, as of Nov 19, 2026.
Is AVTX stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 10 active firms as of Nov 19, 2026, 8 rate it Buy or Strong Buy, 2 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for AVTX?+
The Street-high target is $60.00 (Piper Sandler), and the Street-low is $10.00 (BTIG). The average of all 10 active-firm targets is $39.10.
How many active Wall Street firms cover AVTX?+
10 active firms have a recognized rating on Avalo Therapeutics Inc as of Nov 19, 2026, and 10 active firms carry a live 12-month price target.
Who is the most accurate analyst covering AVTX?+
Among analysts who currently cover AVTX, Jason Butler of JMP Securities has the strongest overall Quantellect track record (Rank #62). Their current call is Buy with a $55.00 target.
What is Avalo Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.62 per share (range $-0.74 – $-0.54) across 4 analysts. Full-year EPS is projected at $-2.35, rising to $-2.62 the following year.
How much revenue is Avalo Therapeutics Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading AVTX lately?+
As of Nov 19, 2026, 8 of 10 active firms rate AVTX a Buy (2 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their AVTX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.